The North America real world data (RWD) market size was estimated at USD 830.00 billion in 2025 and is projected to be worth around USD 2,867.76 billion by 2035, is expanding at a CAGR of 13.20 % from 2026 to 2035. Due to rising demand for data-based healthcare solutions and real-world evidence in medical research. Pharmaceutical and psychology companies are widely used RWD to improve drug development, patient monitoring, and post- market surveillance.

North America Real World Data (RWD) Market Statical Scope

Increasing chronic disease, electronic health records, and supportive healthcare policies are major factors driving market growth across the region.

Technologies such as artificial intelligence , machine learning , cloud computing, and big data analytics are supporting personalized treatment approaches. These technologies help healthcare organisations analyse massive patient data sets efficiently, improve predictive insights, and support personalised medicine , strengthening market growth and innovation.

North America Real World Data (RWD) Market, By Component Share, 2025 (%)

• Services- The services segment dominated the market with a share of 58% in 2025, due to increasing demand of analytics, consulting, data integration, and real- world evidence generation services used in clinical research, health care decision- making, and pharmaceutical development. These services are increasingly utilised in clinical research, pharmaceutical development, regulatory support, patient outcome analysis, and healthcare decision-making processes, rising adoption of data- driving strategies by pharmaceutical companies, healthcare providers, and research organisations is further supporting the expansion of services segment.
• Datasets- The datasets segment are rapidly growing with a market share of 42%, due to growing use of healthcare databases, patient- level clinical information, and large- scale medical data to support research, treatment planning, an evidence- based healthcare decisions.

North America Real World Data (RWD) Market, By Application Share, 2025 (%)

• Drug Development & Approvals- The drug development & approvals segment dominated the market with a share of 31% in 2025, due to growing reduction of real- world evidence for regulatory submissions, clinical decision-making, faster drug development processes, an improved evaluation of treatment safety and effectiveness.
• Market Access & Reimbursement/Coverage Decisions- The market access & reimbursement/coverage decisions segment are rapidly growing with a market share of 18%, due to increasing emphasis on value- based healthcare, reimbursement optimization, cost- effectiveness analysis, an improved healthcare coverage decision-making across the region.
• Post-market Surveillance- The post-market surveillance segment held a 19% market share in 2025 and is expected to grow at a steady rate, due to growing focus on pharmacovigilance, continuous monitoring of drug safety, and the need or track long- term treatment outcomes after product approval.

North America Real World Data (RWD) Market, By End User Share, 2025 (%)

• Pharmaceutical & Medical Device Companies- The pharmaceutical & medical device companies segment dominated the market with a share of 44% in 2025, Due to widespread use of RWD in drug development, product commercialization, post- market analysis, and improving clinical and business decision-making processes.
• Healthcare Payers- The healthcare payers segment held a 17% market share in 2025 and is expected to grow at a steady rate, due to growing use of healthcare analytics for reimbursement planning, coverage decisions, cost management, and improving overall efficiency in healthcare payment systems.
• Healthcare Providers- The healthcare providers segment are rapidly growing with a market share of 22%, Driven in by the increasing Adoption of data-driven patient care, Clinical outcome analysis, And the growing use of real-world Insights to improve healthcare quality and treatment efficiency. Hospitals, clinics and healthcare systems are increasingly relying on real-world data to support personalised treatment planning, monitor patient outcomes, enhance operational efficiency, and improve overall clinical decision-making, the rising integration of electronic health records, digital healthcare platforms, and predictive analytics technologies is also contributing significantly to the growth of the segment.

Recent Developments in the Market

• Thermo Fisher Scientific Partners Health Verity to Advance Data Driven Clinical Development
• In April 2026, Thermo Fisher Scientific, announced a strategic collaboration with Health Verity to strengthen real- world data capabilities, supporting data-driven clinical development in evidence generation for biopharma sponsors through enhanced patient data access, analytics, and research insights.

Competitive Landscape

Key companies operating in the North America real-world market includes IQVIA, Oracle, Optum, Thermo fisher scientific and cognizant. these companies are strengthening the market through advanced analytics, AI-driven healthcare solutions, real-world evident generation, and data integration platforms that support drug development, regulatory decision-making, and patient outcome analysis. Their services are widely used in drug development, regulatory submissions, clinical research, treatment optimization, an improving healthcare decision-making and patient outcome analysis across North America.

Segments Covered in the Report

By Component

• Services
• Datasets

By Application

• Drug Development & Approvals
• Market Access & Reimbursement/Coverage Decisions
• Post-market Surveillance
• Clinical Research
• Other

By End User

• Pharmaceutical & Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Government Agencies
• Others